ACTRN12623000669695尚未招募4 期
A two-arm, parallel-group, open label, randomised controlled feasibility trial assessing the effect of intravenous iron versus no treatment on haemoglobin concentration in anaemic patients undergoing abdominal surgery.
VERITAS Collaborative0 个研究点目标入组 100 人开始时间: 2023年6月21日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients who meet the following criteria:
- •1.Adult (greater than or equal to 18 years of age)
- •2.Patients who have undergone major abdominal surgery during the study recruitment periods
- •3.Anaemia (Hb <130g/L in males, and <120g/L in females) demonstrated on blood tests performed either during or after the procedure
排除标准
- •Patients who, at the start of treatment, meet any of the following criteria are not eligible for the study:
- •1.Erythropoietin or IV iron in the previous 4 weeks
- •2.Known hypersensitivity to iron or its excipients
- •3.Known chronic liver disease
- •4.Known family history of haemochromatosis or Transferrin Saturation (TSATS) >50%
- •5.Pregnancy or lactation
- •6.Unable to provide written informed consent
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy.Idiopathic Membranous nephropathyMedDRA version: 21.1Level: LLTClassification code 10027170Term: Membranous nephropathySystem Organ Class: 100000004857EUCTR2019-001734-34-DEovartis Pharma AG52
进行中（未招募）
1 期
Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy.Idiopathic Membranous nephropathyMedDRA version: 21.1Level: LLTClassification code 10027170Term: Membranous nephropathySystem Organ Class: 100000004857EUCTR2019-001734-34-NLovartis Pharma AG52
进行中（未招募）
不适用
An open-label, randomized, two-arm parallel group study to compare the effects of 4-week QD treatment with lixisenatide or liraglutide on the postprandial plasma glucose in patients with type 2 diabetes not adequately controlled with metformiDiabetesEUCTR2009-017666-23-DEsanofi-aventis
已完成
2 期
A randomized, open-label, parallel group, two arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy.Membranous nephropathyNL-OMON52636ovartis3
已完成
Unknown
A Phase 1 Study to Compare the Pharmacokinetics and Safety of CT-P13 (CT-P13 SC) Auto-injector and Pre-filled Syringe for Subcutaneous Administration in Healthy Adult SubjectsKCT0009574Celltrion148